Glaxo defends handling of Avandia heart risks
Wednesday, February 24, 2010 - 15:42
in Health & Medicine
(AP) -- GlaxoSmithKline said Wednesday a Senate report criticizing its handling of heart risks with its diabetes drug Avandia "mischaracterizes and distorts" the company's record.